Essay: Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies? A Response

References

• Markman M. Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?. Cancer Invest 1996; 14: 498–500
   PubMed Web of Science ®Google Scholar
• Swenerton K, Eisenhauer E, Ten Bokkel Huirnik W W, et al. Taxol in relapsed ovarian cancer: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1993; 12: 256, (abstract)
   Google Scholar
• Omura G A, Brady M F, Delmore J E, et al. A randomized trial of paclitaxel at 2 dose levels and filgrastrim at 2 doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, NCCTG, and ECOG study. Proc Am Soc Clin Oncol 1996; 15: 280, (abstract 755)
   Google Scholar
• Kohn E C, Sarosy G, Bicher A, Link C, Christian M, Steinberg S, Rothenberg M, Adamo D O, Davis P, Ognibene F, Cunnion R., Reed E. Taxol: High dose intensity increases the objective response rate in platinum-resistant ovarian cancer patients. J Natl Cancer Inst 1994; 86: 18–24
   PubMed Web of Science ®Google Scholar
• Levin L, Hyrniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 1987; 5: 756–767
   Google Scholar
• Reed E, Bitton R, Sarosy G, Kohn E. Paclitaxel dose intensity. J Infus Chemother 1996; 6: 59–63
   PubMedGoogle Scholar
• Kohn E C, Sarosy G, Davis P, Christian M, Ognibene F P, Sindelar W F, Jacob J, Steinberg S M, Premkumar A, Reed E. A phase I study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol 1996; 62: 181–191
   PubMed Web of Science ®Google Scholar
• Young R C, Perez C A, Hoskins W J. Cancer of the ovary. Cancer Principles and Practices of Oncology, 4th ed, V T DeVita, S. Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1993; 1226–1263
   Google Scholar
• Reed E. The chemotherapy of ovarian cancer. PPO Updates 1996; 10(7)1–12
   Google Scholar
• Neijt J P, Ten Bokkel Huirnik W W, Van der Burg M E, et al. Long-term survival in ovarian cancer: Mature data from the Netherlands Joint Study Group for ovarian cancer. Eur J Cancer 1991; 27: 1367–1372
   PubMed Web of Science ®Google Scholar
• Thigpen J T, Blessing J A, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynecologic oncology group study. J Clin Oncol 1994; 12: 1748–1753
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Ovarian Cancer, Screening, Treatment, and Follow-up. Member of the Planning Committee. JAMA 1995; 273: 491–197
   PubMed Web of Science ®Google Scholar
• McGuire W, Hoskins W J, Brady M F, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl J Med 1996; 334: 1–6
   PubMed Web of Science ®Google Scholar
• Sarosy G, Kohn E, Stone D A, et al. Phase I study of taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–1170
   PubMed Web of Science ®Google Scholar
• Reed R, Kohn E, Sarosy G, et al. Paclitaxel, cisplatin and cyclophosphamide in human ovarian cancer: molecular rational and early clinical results. Semin Oncol 1995; 22: 90–96
   PubMed Web of Science ®Google Scholar
• Link C J, Bicher A, Kohn F, et al. Flexible G-CSF dosing in ovarian cancer patients receiving dose intense taxol therapy. Blood 1994; 83: 1188–1192
   PubMed Web of Science ®Google Scholar
• Bicher A, Kohn E, Sarosy G, Adamo D O, Davis P., Jacob J., Christian M., Reed E. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose intense taxol and G-CSF. Anti-Cancer Drugs 1993; 4: 141–148
   PubMed Web of Science ®Google Scholar
• Reed E. The use of colony stimulating factors as bone marrow support for systemic anticancer chemotherapy. J Natl Med Assoc 1994; 86: 459–464
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, Doinehower R C. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004–1014
   PubMed Web of Science ®Google Scholar
• Murphy W K, Fossella F V, Winn R J, et al. Phase II study of taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384–388
   PubMed Web of Science ®Google Scholar
• Chang A Y, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. Natl Cancer Inst 1993; 85: 388–394
   Google Scholar
• Ettinger D S, Finkelstein D M, Sarma R, Johnson D H. Phase II study of taxol in patients with extensive-stage small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 329, (abstract)
   Google Scholar
• Kirschling R J, Jung S H, Jett J R. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1993; 13: 326, (abstract)
   Google Scholar
• Forastiere A A, Neuberg D, Taylor S G, Deconti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 1993; 15: 181–184
   PubMedGoogle Scholar
• Motzer R J, Bajorin D F, Schwartz L H, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277–2283
   PubMed Web of Science ®Google Scholar
• Roth B J, Dreicer R, Einhorn L H, et al. Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 1994; 13: 230, (abstract)
   Google Scholar
• Ajani J A, Ilson D H, Daugherty K, Pazdur R, Lynch P M, Kelsen D P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086–1091
   PubMed Web of Science ®Google Scholar
• Ball G H, Blessing J A, Lentz S S, Mutch D G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278–281
   PubMed Web of Science ®Google Scholar
• Markman M. An argument in support of cost-effectiveness analysis in oncology. J Clin Oncol 1988; 6: 937–939
   PubMed Web of Science ®Google Scholar